About us

Evestra Onkologia Sp. z o.o is a Polish biopharmaceutical, clinical stage start-up company located in Lodz launched by a distinguished team with an impressive record in developing and commercializing innovative oncology and other proliferative diseases products.

The Company was launched as a wholly-owned subsidiary of Evestra, Inc., a U.S.A. biopharmaceutical company based in San Antonio, Texas. The key mission of Evestra Onkologia is to develop highly innovative assets in woman’s health area in Poland, and the EU. To accomplish its core mission, the Company has and will continue to establish a variety of fruitful collaborations with leading Polish research institutions and investigators and for-profit CRO companies in Poland, to enhance development and commercialization of its innovative assets.
Dr. Ze’ev Shaked, Ph.D. has multi-disciplinary track record in oncology including development and commercialization of novel antimetabolites to treat hematological cancers, biologics such as cytotoxic monoclonal antibodies and cytokines to treat a wide range of solid tumor indications. Both board members hold numerous patents and have managed R&D departments and projects for many years. Dr Maciej Wierzbicki, Ph.D. has experienced the development of early stage ventures in the field of life science technology, including the acquisition of financing and project management.

Evestra Onkologia is working closely with Evestra INC. on the development and worldwide commercialization of innovative resources.


Our team

Find out more about us


Read older messages

Evestra Onkologia Sp. z o.o. Announced Today Initiation of First-in-Human Phase I Clinical Studies Targeting Endometriosis, Uterine Fibroids and other Gynaecological Disorders

Evestra Onkologia Sp. z o.o. (www.evestraonkologia.pl) announced today initiating of first-in-human (FIH) Phase I clinical studies to assess pharmacokinetics and safety/tolerability of EVE126 (EC313), a novel agonist/antagonist candidate that targets endometriosis, uterine fibroids and other gynaecological indications.

This important  milestone highlights  the company’s dedication to advancing women’s health R&D and quality-of-life through groundbreaking research and development.

EVE126 (EC313) is a new chemical entity (NCE) steroidal small molecule developed via medicinal chemistry structure activity correlation as a third generation SPRM to treat a wide range of women’s health disorders. While first and second generation SPRMs are either pure PR-antagonists or possess very high antagonistic activity, EC313 was designed to possess both PR-antagonistic as well as PR-agonistic activity.

These Phase 1 studies are first, randomized, single-blind, placebo-controlled, single- ascending Dose, and second, multiple dose study evaluating the safety, tolerability, and pharmacokinetics of  oral EC313 in healthy postmenopausal women is divided into two parts.. These Phase I studies  will generate the necessary data necessary to enter Phase II studies and beyond.

Following intensive EC313 drug development efforts in the last few years,  it is especially gratifying to our entire team to enter the clinical phase.  It is a reflection of the company’s “can do” mentality and culture says Evestra Onkologia managing director, Maciej Wierzbicki, PhD

The development of EC313 including the clinical trial conducted by Evestra Onkologia Sp. z o.o. is co-funded by the National Centre for Research and Development (agreement POIR.01.01.01-00-0123/16).

Evestra Onkologia Sp. z o.o. is a Polish biopharmaceutical start-up company located in Łódź,   and established as a wholly-owned subsidiary of Evestra, Inc., a biopharmaceutical company headquartered in San Antonio, Texas, USA.

Read more

EU projects

Website designed and made by Reddog Systems